Trial Profile

The ARDENT Study: Atazanavir, Raltegravir, or Darunavir With Emtricitabine/Tenofovir for Naive Treatment

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atazanavir (Primary) ; Darunavir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Raltegravir (Primary) ; Ritonavir (Primary)
Indications HIV-1 infections
Focus Therapeutic Use
Acronyms ARDENT

30 Jul 2021 Results of ancillary study of this study assessing effects of anti retroviral drugs on changes in lipid profile published in the Medicine.
19 Apr 2021 Results assessing the Association Between Weight Gain, Sex and Immune Activation Following the Initiation of Antiretroviral Therapy from two trials A5202 and A5257 published in the Journal of Infectious Diseases
07 Mar 2018 Results of analysis assessing hair antiretroviral levels as a predictor of virologic outcomes presented at the 25th Conference on Retroviruses and Opportunistic Infections

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com